SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

REGOLI, Domenico
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.926
AS - Asia 4.059
EU - Europa 3.053
SA - Sud America 608
AF - Africa 52
Continente sconosciuto - Info sul continente non disponibili 4
OC - Oceania 3
Totale 17.705
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.760
SG - Singapore 1.631
CN - Cina 1.305
DE - Germania 840
UA - Ucraina 570
BR - Brasile 510
IT - Italia 399
GB - Regno Unito 364
HK - Hong Kong 356
TR - Turchia 355
FI - Finlandia 332
VN - Vietnam 206
RU - Federazione Russa 136
SE - Svezia 129
CA - Canada 94
FR - Francia 82
MX - Messico 52
IN - India 51
PL - Polonia 44
BE - Belgio 41
JP - Giappone 36
AR - Argentina 35
ZA - Sudafrica 27
LT - Lituania 26
NL - Olanda 26
ES - Italia 25
BD - Bangladesh 24
ID - Indonesia 19
EC - Ecuador 17
IQ - Iraq 17
CO - Colombia 11
AE - Emirati Arabi Uniti 9
CL - Cile 8
CZ - Repubblica Ceca 7
IR - Iran 7
PE - Perù 7
PY - Paraguay 7
UY - Uruguay 7
AT - Austria 6
BG - Bulgaria 6
MA - Marocco 6
UZ - Uzbekistan 6
VE - Venezuela 6
DO - Repubblica Dominicana 5
LB - Libano 5
PK - Pakistan 5
SA - Arabia Saudita 5
EG - Egitto 4
IL - Israele 4
NP - Nepal 4
SN - Senegal 4
AL - Albania 3
AU - Australia 3
HR - Croazia 3
JM - Giamaica 3
KE - Kenya 3
PA - Panama 3
TN - Tunisia 3
BH - Bahrain 2
CR - Costa Rica 2
DK - Danimarca 2
EU - Europa 2
GR - Grecia 2
HN - Honduras 2
IE - Irlanda 2
JO - Giordania 2
MY - Malesia 2
RO - Romania 2
SV - El Salvador 2
TT - Trinidad e Tobago 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
AZ - Azerbaigian 1
BY - Bielorussia 1
CG - Congo 1
CH - Svizzera 1
DZ - Algeria 1
EE - Estonia 1
ET - Etiopia 1
GA - Gabon 1
GE - Georgia 1
KH - Cambogia 1
KR - Corea 1
KZ - Kazakistan 1
LU - Lussemburgo 1
LV - Lettonia 1
MM - Myanmar 1
MN - Mongolia 1
NE - Niger 1
NI - Nicaragua 1
NO - Norvegia 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 17.705
Salva come PNG Salva come JPEG
Città #
Fairfield 1.109
Woodbridge 1.076
Singapore 984
Ashburn 948
Houston 659
Jacksonville 614
Ann Arbor 559
Chandler 519
Beijing 454
Santa Clara 412
Seattle 409
Wilmington 392
Hong Kong 355
Cambridge 352
Munich 342
Izmir 193
Nanjing 178
Los Angeles 149
New York 146
Helsinki 138
Milan 131
Dallas 119
Princeton 118
San Diego 109
Boardman 100
Shanghai 75
Ho Chi Minh City 71
Turku 71
Nanchang 57
São Paulo 57
Dearborn 56
Shenyang 51
Hanoi 47
Falls Church 44
Brussels 40
London 39
Tokyo 35
Bremen 33
Brooklyn 33
Falkenstein 33
Hefei 33
Mexico City 33
Hebei 32
Warsaw 32
Ferrara 31
Buffalo 30
Frankfurt am Main 30
Orem 30
Auburn Hills 29
Jiaxing 29
Tianjin 29
Changsha 28
Mountain View 27
San Mateo 27
Jinan 26
Denver 25
Montreal 24
Toronto 23
Mcallen 22
Norwalk 22
Philadelphia 21
Phoenix 21
Johannesburg 20
Moscow 20
Redwood City 20
Addison 19
Atlanta 19
Chicago 18
Kunming 18
Poplar 18
Rio de Janeiro 18
Zhengzhou 18
Montréal 17
San Francisco 17
Boston 16
Bexley 15
Stockholm 15
Manchester 13
Indiana 12
Ningbo 12
Tappahannock 12
Belo Horizonte 11
Mumbai 11
Ankara 10
Chennai 10
Des Moines 10
Guangzhou 10
The Dalles 10
Biên Hòa 9
Curitiba 9
Wroclaw 9
Augusta 8
Bologna 8
Carapicuíba 8
Charlotte 8
Columbus 8
Campinas 7
Düsseldorf 7
Guayaquil 7
Joinville 7
Totale 12.395
Salva come PNG Salva come JPEG
Nome #
[Nphe(1),Arg(14),Lys(15)]nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor 339
AGONISTI PIENI E PARZIALI ED ANTAGONISTI DEL RECETTORE PER NOCICETTINA/ORFANINA FQ AD ELEVATA POTENZA” 285
Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8 ,9-tetrahydro-5H-benzocyclohepten-5-ol]: In vivo studies 274
Characterization of FR 172357, a new non-peptide bradykinin B2 receptor antagonist, in human, pig and rabbit preparations 238
[(pF)Phe4,Arg14,Lys15]N/OFQ-NH2 (UFP-102), a highly potent and selective agonist of the nociceptin/orphanin FQ receptor 232
A new selective antagonist of the nociceptin receptor 231
Human vascular kinin receptors of the B-2 type characterized by radioligand binding 220
A new ligand for the urotensin II receptor 215
Kinin B-1 and B-2 receptors in pig vessels: characterization of two monoreceptor systems 212
In vitro and in vivo studies on UFP-112, a novel potent and long lasting agonist selective for the nociceptin/orphanin FQ receptor 208
Structure-activity studies on the nociceptin/orphanin FQ receptor antagonist 1-benzyl-N-{3-[spiroisobenzofuran-1(3H),4′-piperidin-1-yl]propyl} pyrrolidine-2-carboxamide 203
Tryptophan replacement in the nociceptin/orphanin FQ receptor ligand Ac-RYYRWK-NH2 203
N- and C-terminal modifications of nociceptin/orphanin FQ generate highly potent NOP receptor ligands 203
Identification of an achiral analogue of J-113397 as potent nociceptin/orphanin FQ receptor antagonist 199
Conformation-activity relationship of neuropeptide S and some structural mutants: Helicity affects their interaction with the receptor 196
Effects of vasoactive agents in healthy and diseased human saphenous veins 191
Ala scan analogues of HOE 140. Synthesis and biological activities 189
Address and message sequences for the nociceptin receptor: A structure-activity study of nociceptin-(1-13)-peptide amide 188
Dmt-Tic-NH-CH2-Bid (UFP-502), a potent DOP receptor agonist: In vitro and in vivo studies 184
Synthesis and biological activity of human neuropeptide S analogues modified in position 2 184
UFP-112 a Potent and Long-Lasting Agonist Selective for the Nociceptin/Orphanin FQ Receptor 184
Endogenous nociceptin/orphanin FQ signalling produces opposite spinal antinociceptive and supraspinal pronociceptive effects in the mouse formalin test: Pharmacological and genetic evidences 183
UFP-101 antagonizes the spinal antinociceptive effects of nociceptin/orphanin FQ; Behavioral and electrophysiological studies in mice 183
Further studies on nociceptin-related peptides: Discovery of a new chemical template with antagonist activity on the nociceptin receptor 181
Pharmacological characterization of the nociceptin/orphanin FQ receptor non peptide antagonist Compound 24 180
[Nphe(1)]nociceptin-(1-13)NH2 selectively antagonizes nociceptin effects in the rabbit isolated ileum 179
Anxiolytic- and antidepressant-like activities of H-Dmt-Tic-NH-CH(CH2-COOH)-Bid (UFP-512), a novel selective delta opioid receptor agonist 179
Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl] methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: In vitro studies 179
In vitro and in vivo pharmacological characterization of the novel NK(1) receptor selective antagonist Netupitant. 177
Effects of human urotensin II in isolated vessels of various species; comparison with other vasoactive agents 176
Pharmacological characterization of nociceptin receptor: an in vitro study 176
Further studies at neuropeptide S position 5: Discovery of novel neuropeptide S receptor antagonists 175
Structure-activity study of the nociceptin(1-13)-NH2 N-terminal tetrapeptide and discovery of a nociceptin receptor antagonist 174
Pharmacological characterization of the nociceptin receptor mediating hyperalgesia in the mouse tail withdrawal assay 172
Pharmacological characterisation of novel kinin B2 receptor ligands 170
Urotensin II stimulates plasma extravasation in mice via UT receptor activation 170
B1 and B2 kinin receptors in various species 169
[Arg(14), Lys(15)]nociceptin, a highly potent agonist of the nociceptin/orphanin FQ receptor: in vitro and in vivo studies 168
Characterization of [Nphe(1)]nociceptin(1-13)NH2, a new selective nociceptin receptor antagonist 167
Synthesis and biological activity of nociceptin/orphanin FQ analogues substituted in position 7 or 11 with C alpha,alpha-dialkylated amino acids 166
Structure-activity study at positions 3 and 4 of human neuropeptide S. 164
Pharmacology of [Tyr(1)]nociceptin analogs: receptor binding and bioassay studies 163
Altered anxiety-related behavior in nociceptin/orphanin FQ receptor gene knockout mice 163
Neuropeptide S is a stimulatory anxiolytic agent: A behavioural study in mice 163
Characterization of nociceptin receptors in the periphery: in vitro and in vivo studies 162
Changes in hippocampal and cortical B1 bradykinin receptor biological activity in two experimental models of epilepsy 162
Nociceptin receptor activation inhibits tachykinergic non adrenergic non cholinergic contraction of guinea pig isolated bronchus 162
Synthesis and Biological Activity of Human Neuropeptide S Analogues Modified in Position 5: Identification of Potent and Pure Neuropeptide S Receptor Antagonists 161
Autoradiographic analysis of rat brain kinin B-1 and B-2 receptors: Normal distribution and alterations induced by epilepsy 160
Structure-activity relationship study of position 4 in the urotensin-II receptor ligand U-II(4-11) 158
Pharmacological profile of NOP receptors coupled with calcium signaling via the chimeric protein Gαqi5 157
The nociceptin/orphanin FQ receptor antagonist, [Nphe(1)]NC(1-13)NH2, potentiates morphine analgesia 155
In vitro and in vivo pharmacological characterization of the neuropeptide S receptor antagonist [D-Cys(tBu)5]neuropeptide S 152
Bradykinin receptors and receptor ligands (with special emphasis on vascular receptors) 151
Characterization of the human vascular kinin B2 receptor by binding assays. 151
Studies on the antinociceptive effect of [Nphe(1)]nociceptin(1-13)NH2 in mice 150
Anxiolytic and antidepressant-like activities of UFP-512, a novel selective delta opiold receptor agonist 150
Angiotensin II-induced increase of T-type Ca2+ current and decrease of L-type Ca2+ current in heart cells 150
Urantide mimics urotensin-II induced calcium release in cells expressing recombinant UT receptors 150
Structure-activity relationship study on Tyr9 of urotensin-II(4-11): Identification of a partial agonist of the UT receptor 149
Pharmacological profile of hemokinin 1: a novel member of the tachykinin family 146
Structure-activity relationship study on human urotensin II 146
Characterization of endothelin receptors in the human umbilical artery and vein 145
Nociceptin/orphanin FQ receptor ligands 143
Urotensin II-induced hypotensive responses in Wistar-Kyoto (Wky) and spontaneously hypertensive (Shr) rats 142
The mouse vas deferens: A pharmacological preparation sensitive to nociceptin 142
Nociceptin receptor binding in mouse forebrain membranes: Thermodynamic characteristics and structure activity relationships 141
Pharmacology of the Kallikrein-Kinin system 141
In vitro and in vivo pharmacological characterization of the novel UT receptor ligand [Pen(5), DTrp(7), Dab(8)] urotensin II(4-11) (UFP-803) 140
Structure-activity studies on neuropeptide S - Identification of the amino acid residues crucial for receptor activation 139
Receptors for kinins in the human isolated umbilical vein 137
Bradykinin B2 receptors increase hippocampal excitability and susceptibility to seizures in mice 137
ANTAGONISTI DEL RECETTORE UT E LORO USI TERAPEUTICI 136
Neurobiology, pharmacology, and medicinal chemistry of neuropeptide S and its receptor 136
Effects of intrathecal nocistatin on the flexor reflex and its interaction with orphanin FQ nociceptin 136
UFP-101, a peptide antagonist selective for the nociceptin/orphanin FQ receptor 136
ANALOGHI DERMASEPTINICI AD ATTIVITA’ ANTIMICROBICA 136
In vitro characterization of J-113397, a non-peptide nociceptin/orphanin FQ receptor antagonist 135
In vitro pharmacological profile of peptide III-BTD: A novel ligand for nociceptin/orphanin FQ and opioid receptors 134
Pharmacology of nociceptin and its receptor: a novel therapeutic target 133
Effects of Ro 64-6198 it nociceptin/orphanin FQ-sensitive isolated tissues 130
In vitro characterization of FR 190997, the first non peptide B2 receptor agonist receptor binding and bioassay in the human umbilical vein 128
Structure-activity studies of the Phe(4) residue of nociceptin(1-13)-NH2: Identification of highly potent agonists of the nociceptin/orphanin FQ receptor 128
Nociceptin/orphanin FQ inhibits electrically induced contractions of the human bronchus via NOP receptor activation 127
Effects of naloxone benzoylhydrazone on native and recombinant nociceptin/orphanin FQ receptors 125
FR 173657: a new, potent, nonpeptide kinin B2 receptor antagonist. An in vitro study 124
Contractile activity of endothelins and their precursors in human umbilical artery and vein: identification of distinct endothelin-converting enzyme activities 123
Angiotensin II induced increase in frequency of cytosolic and nuclear calcium waves of heart cells via activation of AT(1) and AT(2) receptors 121
Pharmacology of [tyr1]nociceptin analogs: receptor binding and bioassay studies 118
Receptor binding profile of novel nociceptin/orphanin FQ receptor ligands in mouse brain membranes. 116
Further studies on nociceptin/orphanin FQ related peptides: discovery of a new chemical template with antagonist activity on the OP4 receptor. 114
Further studies on nociceptin related peptides: discovery of new molecules with antagonist activity on the nociceptin receptor 114
Nociceptin receptor antagonists display antidepressant-like properties in the mouse forced swimming test 111
Pharmacological characterisation of [(pX)Phe(4)]nociceptin(1-13)amide analogues - 1. In vitro studies 105
Expression and biological activity of B1 bradykinin receptors in two experimental models of epilepsy 105
Pharmacological characterization of the nociceptin receptors in the mouse: receptor binding, bioassay and behavioral studies 103
Highly potent full and partial agonists and anatagonists of the nociceptin/orphanin FQ receptor 102
null 99
null 98
Identificazione di un antagonista del recettore UT 95
Totale 16.102
Salva come PNG Salva come JPEG
Categoria #
all - tutte 80.137
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 80.137
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021853 0 0 0 0 0 159 53 177 30 166 204 64
2021/20221.308 44 137 96 98 87 56 73 72 57 94 123 371
2022/20231.332 125 50 62 168 224 176 112 100 196 7 68 44
2023/2024631 76 78 37 16 39 133 21 42 13 12 14 150
2024/20252.785 54 51 206 106 337 315 133 177 397 244 405 360
2025/20263.988 827 316 632 996 1.142 75 0 0 0 0 0 0
Totale 17.810